VandanaGupta(Gupta)AbramsonMD

Oncology • Nashville, TN

Breast Cancer, Hematologic Oncology

Professor, Medicine (Oncology), Vanderbilt University School of Medicine

Join to view full profile

Dr. Abramson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Abramson's full profile

Already have an account?

Office
719 Thompson Ln
Ste 30860
Nashville, TN 37204
Phone+1 615-936-8422

Fax+1 615-343-3212
Is this information wrong?

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2003 - 2006
Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2000

Certifications & Licensure

TN State Medical License 2010 - 2025
TN State Medical License 2020 - 2025
TN State Medical License 2008 - 2025
AL State Medical License 2020 - 2020
PA State Medical License 2003 - 2008

Clinical Trials

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer Start of enrollment: 2011 Feb 01
Withdrawn
Phase 2
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases Start of enrollment: 2011 Sep 01
Completed
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01
Active, not recruiting
Phase 2
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer Start of enrollment: 2013 Sep 01
Terminated
Phase 1, Phase 2
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer Start of enrollment: 2014 Jan 30
Active, not recruiting
Phase 2
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer Start of enrollment: 2014 Apr 01
Completed
Phase 2
Bioimpedance Spectroscopy Versus Tape Measure in Prevention of Lymphedema (PREVENT) Start of enrollment: 2014 Jun 01
Completed
Not Applicable
BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer Start of enrollment: 2015 Feb 01
Completed
Phase 1, Phase 2
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Start of enrollment: 2015 Jun 01
Terminated
Phase 1, Phase 2
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer Start of enrollment: 2016 Jan 28
Completed
Phase 2
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer Start of enrollment: 2016 Mar 01
Completed
Phase 1
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer Start of enrollment: 2021 Jan 11
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy Start of enrollment: 2023 Oct 02
Suspended
Phase 2
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer.
Taylor, B., Sun, X., Gonzalez-Ericsson, P., Sanchez, V., Sanders, M., Wescott, E., Opalenik, S., Hanna, A., Chou, S., Van Kaer, L., Gomez, H., Isaacs, C., Ballinger, T...> ;Cancer Discovery. 2024 Feb 8
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.
Zheqi Li, Otto Metzger Filho, Giuseppe Viale, Patrizia dell'Orto, Leila Russo, Marie-Anne Goyette, Avni Kamat, Denise A Yardley, Vandana Gupta Abramson, Carlos L Artea...> ;The Journal of Clinical Investigation. 2024 Feb 1
1 citations
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical...
Lehmann, B., Abramson, V., Dees, E., Shah, P., Ballinger, T., Isaacs, C., Santa-Maria, C., An, H., Gonzalez-Ericsson, P., Sanders, M., Newsom, K., Abramson, R., Sheng,...> ;JAMA Oncology. 2024 Feb 1
2 citations
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).
Maeve A Hennessy, Jeffrey P Leal, Chiung-Yu Huang, Lilja B Solnes, Rita Denbow, Vandana G Abramson, Lisa A Carey, Minetta C Liu, Mothaffar Rimawi, Jennifer Specht, Ann...> ;Journal of Nuclear Medicine. 2023 Nov 1
1 citations
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Lauren Lenz, Chris Neff, Cara Solimeno, Elizabeth S Cogan, Vandana G Abramson, Judy C Boughey, Carla Falkson, Matthew P Goetz, James M Ford, William J Gradishar, Rache...> ;Breast Cancer Research and Treatment. 2023 Nov 1
1 citations
Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospe...
Meridith L Balbach, Alexander D Sherry, Brent N Rexer, Vandana G Abramson, Kenneth J Niermann, Corbin R Johnson, Ben Ho Park, Ingrid A Mayer, A Bapsi Chakravarthy> ;International Journal of Radiation Oncology, Biology, Physics. 2024 Apr 1
3 citations
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Heather A Parsons, Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong, Vandana G Abramson, Ashka Patel, Ju Cheng, Adam Brufsky, Justin Rhoade...> ;Medrxiv. 2023 Mar 8
2 citations
Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer.
Eric M Lander, Katherine C Rappazzo, Li-Ching Huang, Jiun-Ruey Hu, Heidi Chen, Yu Shyr, Vandana G Abramson> ;The Oncologist. 2023 Feb 8
40 citations
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Bra...
Nancy U Lin, Rashmi K Murthy, Vandana Abramson, Carey Anders, Thomas Bachelot, Philippe L Bedard, Virginia Borges, David Cameron, Lisa A Carey, A Jo Chien, Giuseppe Cu...> ;JAMA Oncology. 2023 Feb 1
1 citations
Prospective Surveillance with Compression for Subclinical Lymphedema: Symptoms, Skin, and Quality-of-Life Outcomes.
Mary S Dietrich, Katrina Gaitatzis, Louise Koelmeyer, John Boyages, Vandana G Abramson, Sarah A McLaughlin, Nicholas Ngui, Elisabeth Elder, James French, Jeremy Hsu, T...> ;Lymphatic Research and Biology. 2023 Jun 1
66 citations
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.
Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, Timothy J Whelan, Marguerite Ennis, Julie Lemieux, Jennifer A Ligibel, Dawn L Hershman, Ingrid A Mayer, Timothy J Hob...> ;JAMA. 2022 May 24
16 citations
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Melinda L Telli, Sara M Tolaney, Geoffrey I Shapiro, Mark Middleton, Simon R Lord, Hendrik Tobias Arkenau, Andrew Tutt, Vandana Abramson, Emma Dean, Tufia C Haddad, Ro...> ;NPJ Breast Cancer. 2022 Apr 7
8 citations
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TB...
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani...> ;NPJ Breast Cancer. 2022 Feb 16
26 citations
A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention.
Sheila H Ridner, Mary S Dietrich, John Boyages, Louise Koelmeyer, Elisabeth Elder, T Michael Hughes, James French, Nicholas Ngui, Jeremy Hsu, Vandana G Abramson, Andre...> ;Lymphatic Research and Biology. 2022 Dec 1
13 citations
A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC)
Julie Means-Powell, Ingrid A. Mayer, Roohi Ismail-Khan, Luis Del Valle, Debra A. Tonetti, Vandana G. Abramson, Melinda Sanders, Richard M Lush, Claudia Sorrentino, Sam...> ;Clinical Breast Cancer. 2021 Oct 28
14 citations
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Tr...
Kathryn J. Ruddy, Yue Zheng, Nabihah Tayob, Jiani Hu, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose,...> ;Breast Cancer Research and Treatment. 2021 Jun 12
62 citations
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Sara M. Tolaney, Nabihah Tayob, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose, Jiani Hu, Douglas Wec...> ;Journal of Clinical Oncology. 2021 Jun 2
20 citations
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Roisin M. Connolly, Jeffrey P. Leal, Lilja B. Solnes, Chiung-Yu Huang, Ashley Carpenter, Katy Gaffney, Vandana G Abramson, Lisa A. Carey, Minetta C. Liu, Mothaffar F. ...> ;Journal of Clinical Oncology. 2021 May 17
19 citations
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer.
Chi Yan, Jinming Yang, Nabil Saleh, Sheau-Chiann Chen, Gregory D. Ayers, Vandana G Abramson, Ingrid A. Mayer, Ann Richmond> ;International Journal of Molecular Sciences. 2021 May 14
71 citations
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.
Otto Metzger Filho, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G Abramson, Carlos L. Arteaga, Laura Spring, Adrienne G. ...> ;Cancer Discovery. 2021 May 3
26 citations
Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer
Priyanka Sharma, Vandana G Abramson, Anne O'Dea, Lauren Nye, Ingrid A. Mayer, Harsh B. Pathak, Marc Hoffmann, Shane R. Stecklein, Manana Elia, Sharon Lewis, Jecinta Sc...> ;Clinical Cancer Research. 2021 Feb 18
16 citations
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
Andrew M Wardley, Javier Cortes, Louise Provencher, Kathy D. Miller, A. Jo Chien, Hope S. Rugo, Joyce Steinberg, Jennifer Sugg, Iulia Cristina Tudor, M.T. Huizing, Rob...> ;Breast Cancer Research and Treatment. 2021 Feb 16
81 citations
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
Kevin Kalinsky, Jennifer R. Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric, Joyce O'Shaughnessy, RL Moroose, Ingrid A. Mayer, Vandana G. Abramson, David M. Gol...> ;Annals of Oncology. 2020 Dec 1
41 citations
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biom...
Erica L. Mayer, Vandana G. Abramson, Rachel C. Jankowitz, Carla I. Falkson, Paul K. Marcom, Tiffany A. Traina, Lisa A. Carey, Mothaffar F. Rimawi, Jennifer M. Specht, ...> ;Annals of Oncology. 2020 Nov 1
24 citations
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
Ian E. Krop, Vandana G. Abramson, Marco Colleoni, Tiffany A. Traina, Frankie A. Holmes, Laura García-Estévez, Lowell L. Hart, Ahmad Awada, Claudio Zamagni, Patrick G. ...> ;Clinical Cancer Research. 2020 Sep 28
Join now to see all

Press Mentions

Ridner Concludes Five-Year, Multi-Site Trial to Assess Lymphedema PreventionApril 28th, 2022
CDC Reports Major Drop in Routine Cancer Screenings Due to Ongoing PandemicAugust 14th, 2021
A Brighter Outlook for Metastatic Breast CancerNovember 1st, 2019
Join now to see all

Grant Support

Pet-Mri For Assessing Treatment Response In Breast Cancer Clinical TrialsNational Cancer Institute2010–2012
AKT Inhibitor Mk-2206 For Breast Cancers With A PIK3CA Mutation AND/OR PTEN LossNational Cancer Institute2011